Biotechnology
Ipsen's $1.75 billion acquisition of Kartos Therapeutics brings navtemadlin, a novel MDM2 inhibitor, to myelofibrosis patients who have failed ruxolitinib. The drug targets a complementary pathway with promising Phase 1b/2 data showing disease modification signals.
Biotechnology
Viridian Therapeutics' Lumvoa becomes the second FDA-approved treatment for thyroid eye disease, offering new hope for patients with both active and chronic TED.
Pharmaceuticals
The FDA's approval of Ionis's Tryngolza for severe hypertriglyceridemia marks a pivotal moment for RNA medicine, expanding the drug's reach to three million Americans and signaling that RNA-targeting therapies can compete in large, prevalent disease populations.
Biotechnology
A clinical trial about to begin in the DRC will test the first antivirals against Bundibugyo ebolavirus in a randomized controlled trial. What happens over the coming weeks will matter far beyond the outbreak itself.
Biotechnology
China's approval of CARsgen's satri-cel marks the world's first CAR-T therapy for solid tumors. Here's what it means for the future of cellular immunotherapy and the long-standing barrier between engineered T cells and solid tumor oncology.
Biotechnology
Definium's Phase 3 trial shows DT120, an LSD-based treatment, produced an 8.1-point placebo-adjusted improvement in depression symptoms at six weeks with effects visible within the first week.
Pharmaceuticals
AbbVie's $10.9 billion acquisition of Apogee Therapeutics signals a strategic shift in immunology drug development. The deal centers on zumilokibart, a long-acting IL-13 inhibitor designed to compete with Dupixent through superior dosing convenience.
Pharmaceuticals
On June 18, 2026, an FDA panel voted unanimously to advance Moderna's mRNA flu vaccine, mFlusiva. But the real story isn't the vote—it's the extraordinary regulatory turmoil that preceded it, and what it reveals about vaccine policy in America.
Biotechnology
F2G and Shionogi announce positive phase 3 data for olorofim, the first new antifungal class in over two decades, showing non-inferiority to AmBisome in treating invasive aspergillosis.
Biotechnology
Takeda's oveporexton represents the first direct restoration of orexin signaling in narcolepsy type 1, addressing the root cause rather than managing symptoms. Phase 3 data show improvements in functioning, cognition, and sleep architecture approaching normative levels.
Biotechnology
Intellia's lonvo-z CRISPR therapy delivered Phase 3 data showing 87% reduction in HAE attacks and 51% of patients attack-free at six months. If approved, it would be the first in vivo CRISPR therapy cleared by the FDA, and the implications extend far beyond hereditary angioedema.
Pharmaceuticals
Sanofi's Tzield becomes the first disease-modifying therapy approved for children with stage 3 type 1 diabetes, marking a historic shift from managing symptoms to treating the underlying disease.